MET and neoplasm: The ability of HVS to inhibit the oncogenic human c-Met mutant M1250T with almost equal potency compared with the wild-type receptor in cell-free assays, supported by in silico docking studies (Figures 2B and 3, respectively), provides a stepping stone to: broaden the oleocanthal-based esters therapeutic scope as anticancer agent; cover clinical populations with higher expression levels of this mutant variant; and offer efficacy insights for use to control aggressive tumor phenotypes expressing mutant c-Met constructs.